journal article·2023-10Open access

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Zhicheng Xiao, Yi Li, Liyan Xiong, Jun Liao, Yijun Gao, Yunchun Luo, Yun Wang, Ting Chen, Dahai Yu, Tingfang Wang, Chuan Zhang, Zhe‐Sheng Chen

Advanced Science· Volume 10· Issue 29

Abstract

Abstract Atherosclerosis, the leading cause of death worldwide, is responsible for ≈17.6 million deaths globally each year. Most therapeutic drugs for atherosclerosis have low delivery efficiencies and significant side effects, and this has hampered the development of effective treatment strategies. Diversified nanomaterials can improve drug properties and are considered to be key for the development of improved treatment strategies for atherosclerosis. The pathological mechanisms underlying atherosclerosis is summarized, rationally designed nanoparticle‐mediated therapeutic strategies, and potential future therapeutic targets for nanodelivery. The content of this study reveals the potential and challenges of nanoparticle use for the treatment of atherosclerosis and highlights new effective design ideas.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Atherosclerosis and Cardiovascular Diseases · Phagocytosis and Immune Regulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Engineering Research Center of Organ Repair School of Medicine Shanghai University Shanghai 200444 China

Weihai Medical Area 970 Hospital of Joint Logistic Support Force of PLA Weihai 264200 China

Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John's University New York 11439 USA

Funding

Natural Science Foundation of Shanghai Municipality

References (100+)

Show source-provided references
1. 10.1038/nature1014610.1038/nature10146 ↗
2. 10.1038/nature0132310.1038/nature01323 ↗
3. 10.1161/CIR.000000000000075710.1161/CIR.0000000000000757 ↗
4. 10.1093/eurheartj/ehr15810.1093/eurheartj/ehr158 ↗
5. 10.1038/nrcardio.2018.310.1038/nrcardio.2018.3 ↗
6. 10.1073/pnas.84.16.592810.1073/pnas.84.16.5928 ↗
7. Han L. · Drug Deliv · 2016 · 23 · 1955
8. 10.1038/s41392-021-00631-210.1038/s41392-021-00631-2 ↗
9. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
10. 10.1002/adma.20211066010.1002/adma.202110660 ↗
11. 10.1002/smll.20170279310.1002/smll.201702793 ↗
12. 10.1016/j.addr.2021.01.00510.1016/j.addr.2021.01.005 ↗
13. 10.14797/mdcj-8-1-3610.14797/mdcj-8-1-36 ↗
14. 10.1007/s10311-018-0807-710.1007/s10311-018-0807-7 ↗
15. 10.1016/j.carbpol.2022.11994010.1016/j.carbpol.2022.119940 ↗
16. 10.1016/j.cell.2022.04.00410.1016/j.cell.2022.04.004 ↗
17. 10.1016/j.ccc.2019.12.00910.1016/j.ccc.2019.12.009 ↗
18. 10.1111/apha.1264610.1111/apha.12646 ↗
19. 10.1038/nrd462310.1038/nrd4623 ↗
20. 10.1021/nn502372n10.1021/nn502372n ↗
21. 10.1161/CIRCRESAHA.115.30630110.1161/CIRCRESAHA.115.306301 ↗
22. 10.1182/blood-2014-11-61104610.1182/blood-2014-11-611046 ↗
23. 10.1016/j.celrep.2019.09.03510.1016/j.celrep.2019.09.035 ↗
24. 10.3389/fimmu.2016.0027510.3389/fimmu.2016.00275 ↗
25. 10.1016/j.cmet.2005.01.00210.1016/j.cmet.2005.01.002 ↗
26. 10.1161/CIRCRESAHA.119.31593910.1161/CIRCRESAHA.119.315939 ↗
27. 10.1161/CIRCRESAHA.114.30073810.1161/CIRCRESAHA.114.300738 ↗
28. 10.1161/CIRCRESAHA.115.30636110.1161/CIRCRESAHA.115.306361 ↗
29. 10.1056/NEJM20050728353042510.1056/NEJM200507283530425 ↗
30. 10.1056/NEJM19990114340020710.1056/NEJM199901143400207 ↗
31. 10.1161/ATVBAHA.117.30957510.1161/ATVBAHA.117.309575 ↗
32. 10.1016/j.cmet.2018.05.02710.1016/j.cmet.2018.05.027 ↗
33. 10.1038/s41467-020-17491-z10.1038/s41467-020-17491-z ↗
34. 10.1038/nri345210.1038/nri3452 ↗
35. 10.1038/s41467-018-06607-110.1038/s41467-018-06607-1 ↗
36. 10.1093/gerona/glu19710.1093/gerona/glu197 ↗
37. 10.1161/CIRCRESAHA.117.31198410.1161/CIRCRESAHA.117.311984 ↗
38. 10.1016/S0140-6736(21)00520-110.1016/S0140-6736(21)00520-1 ↗
39. 10.1186/s12916-019-1457-810.1186/s12916-019-1457-8 ↗
40. 10.1093/cvr/cvw19410.1093/cvr/cvw194 ↗
41. 10.1093/eurheartj/ehz746.079910.1093/eurheartj/ehz746.0799 ↗
42. 10.1161/CIRCULATIONAHA.111.05740610.1161/CIRCULATIONAHA.111.057406 ↗
43. 10.1093/eurheartj/ehv70710.1093/eurheartj/ehv707 ↗
44. 10.1056/NEJMoa170148810.1056/NEJMoa1701488 ↗
45. 10.1007/s40265-021-01473-610.1007/s40265-021-01473-6 ↗
46. 10.1016/j.jacc.2023.02.01810.1016/j.jacc.2023.02.018 ↗
47. 10.1182/blood.V118.21.2203.220310.1182/blood.V118.21.2203.2203 ↗
48. 10.1161/ATVBAHA.118.31113910.1161/ATVBAHA.118.311139 ↗
49. 10.1111/jth.1416110.1111/jth.14161 ↗
50. 10.1007/s11883-022-01023-910.1007/s11883-022-01023-9 ↗
51. Gryglewski R. J. · Pol J Pharmacol · 1995 · 47 · 467
52. 10.1038/s42255-019-0100-510.1038/s42255-019-0100-5 ↗
53. 10.1038/nri.2017.2810.1038/nri.2017.28 ↗
54. 10.1056/NEJMra05272310.1056/NEJMra052723 ↗
55. 10.1016/j.atherosclerosis.2005.03.00710.1016/j.atherosclerosis.2005.03.007 ↗
56. 10.1039/D0BM00418A10.1039/D0BM00418A ↗
57. 10.1038/nbt.198910.1038/nbt.1989 ↗
58. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
59. 10.1016/j.immuni.2010.05.00710.1016/j.immuni.2010.05.007 ↗
60. 10.1007/s12272-016-0820-y10.1007/s12272-016-0820-y ↗
61. 10.1038/s41577-019-0240-610.1038/s41577-019-0240-6 ↗
62. 10.1016/j.immuni.2019.04.01810.1016/j.immuni.2019.04.018 ↗
63. 10.1161/01.CIR.97.23.230710.1161/01.CIR.97.23.2307 ↗
64. 10.1038/nri267510.1038/nri2675 ↗
65. 10.1161/CIRCULATIONAHA.116.02568410.1161/CIRCULATIONAHA.116.025684 ↗
66. 10.1161/CIRCRESAHA.121.32070410.1161/CIRCRESAHA.121.320704 ↗
67. 10.1161/ATVBAHA.118.31022710.1161/ATVBAHA.118.310227 ↗
68. Wang C. · J. Immunol. · 2009 · 184 · 21
69. 10.1126/science.118986210.1126/science.1189862 ↗
70. 10.1038/nrd157610.1038/nrd1576 ↗
71. 10.1016/j.ijpharm.2019.02.00410.1016/j.ijpharm.2019.02.004 ↗
72. 10.3390/molecules2305116110.3390/molecules23051161 ↗
73. 10.1080/10717540026674010.1080/107175400266740 ↗
74. 10.1016/j.molliq.2018.04.09810.1016/j.molliq.2018.04.098 ↗
75. 10.1016/j.carbpol.2022.11963210.1016/j.carbpol.2022.119632 ↗
76. 10.1016/j.copbio.2016.02.00810.1016/j.copbio.2016.02.008 ↗
77. 10.1016/j.biomaterials.2017.01.02910.1016/j.biomaterials.2017.01.029 ↗
78. 10.1016/j.addr.2015.11.01110.1016/j.addr.2015.11.011 ↗
79. 10.1039/D2BM00603K10.1039/D2BM00603K ↗
80. Krolikoski M. · Matrix Biol. · 2018 · 78 · 201
81. 10.1517/17425247.2014.87744210.1517/17425247.2014.877442 ↗
82. 10.1021/acsami.7b1609610.1021/acsami.7b16096 ↗
83. 10.1186/s12951-022-01296-x10.1186/s12951-022-01296-x ↗
84. 10.3389/fphar.2018.0126010.3389/fphar.2018.01260 ↗
85. 10.1016/0142-9612(96)85754-110.1016/0142-9612(96)85754-1 ↗
86. 10.1586/erm.09.1510.1586/erm.09.15 ↗
87. 10.1016/j.ijbiomac.2022.08.06310.1016/j.ijbiomac.2022.08.063 ↗
88. 10.1080/15548627.2022.210825210.1080/15548627.2022.2108252 ↗
89. 10.3389/fchem.2022.86806310.3389/fchem.2022.868063 ↗
90. 10.1016/j.matdes.2022.11115510.1016/j.matdes.2022.111155 ↗
91. 10.1016/j.nantod.2012.01.00210.1016/j.nantod.2012.01.002 ↗
92. 10.1016/j.jconrel.2014.06.04210.1016/j.jconrel.2014.06.042 ↗
93. 10.1016/j.jddst.2021.10247310.1016/j.jddst.2021.102473 ↗
94. 10.1016/j.biomaterials.2021.12081010.1016/j.biomaterials.2021.120810 ↗
95. 10.3390/pharmaceutics1405093510.3390/pharmaceutics14050935 ↗
96. 10.1016/j.colsurfb.2019.11071810.1016/j.colsurfb.2019.110718 ↗
97. 10.1016/j.biomaterials.2015.12.02810.1016/j.biomaterials.2015.12.028 ↗
98. 10.3390/ma1110184510.3390/ma11101845 ↗
99. 10.1016/j.arabjc.2020.10293410.1016/j.arabjc.2020.102934 ↗
100. 10.1016/j.carbpol.2017.10.09810.1016/j.carbpol.2017.10.098 ↗